Lactospore® : Lactobacillus sporogenes (coagulans) revivable spores, stable, producing acid L (+) Lactic

Becarre natural

Easy to use probiotic providing 15 billion Lactobacillus sporogenes spores (also called coagulans), stable. Activities are multiple, interacting for the whole body, including digestion, cholesterol management and health of the intestinal tract.
After ingestion (medium for awakening), the spores revive and produce acid L (+) Lactic, with the positive action on other micro-organisms. Lacstorpore is used in dietary supplements, in dairy products, bakery products, in tablets or vaginal ovules and in veterinary products..




Nutritional and therapeutic benefits

Fig.1 - Nutritional and therapeutic benefits



Hypocholesterolemic effects

Fig. 2 - Hypocholesterolemic effects



Change in vaginal pH with treatment

Fig.3 - Change in vaginal pH with treatment



Recommended doses per animal species

Fig.4 - Veterinary - Recommended doses per animal species



Becarre Natural

About LactoSpore®

LactoSpore® is a lactic acid producing Bacillus preparation manufactured and distributed by the SABINSA CORPORATION. This section reviews the background, nutritional and therapeutic aspects and current status of the use of lactic acid producing bacillus preparations, and presents arguments for the superiority of LactoSpore® over other such products in the market, known as "probiotics", used in microbiotherapy.

The foundations of probiotic (meaning "in favor of life") microbiotherapy lie in the postulate of Metchnikoff, a Russian physician, that the growth of toxin-producing putrefactive organisms in the gastrointestinal tract could be controlled by the implantation of beneficial lactobacilli in the gut. The clinical application of preparations containing lactobacilli was initiated on the basis of Metchnikoff's THEORY OF LONGEVITY, which associates with prolonged youthfulness and a healthy old age with the continuous ingestion of lactobacilli. Metchnikoff attributed the longevity of the residents of the Balkan countries to the regular consumption of Bulgarian buttermilk 1. In the early 1900's, he claimed to have successfully cured many of his patients who suffered from a wide variety of organic illnesses, ranging from dryness of skin and gastrointestinal disorders to atherosclerosis, through the therapeutic use of Lactobacilli.

Nutritional and Therapeutic aspects

Fermented milk products have been used therapeutically in the ancient systems of medicine in the Near and Middle East for centuries. However, the nutritional and therapeutic value of lactic acid organisms is still controversial. Several preclinical and clinical studies have been performed, showing that fermentation of food with lactobacilli increases the quantity, availability, digestibility and assimilability of nutrients. A number of studies also show that ingestion of preparations containing lactobacilli lowers the serum cholesterol level in humans and animals. Fermented dairy products have also been claimed to inhibit tumor proliferation and to enhance the immune functions. Fermented dairy products and lyophilized lactobacilli preparations have also proved to be useful in the prevention and treatment of gastrointestinal disorders such as constipation and infections such as salmonellosis, shigellosis and antibiotic- induced diarrhea. Lactobacillus GG has been useful in the treatment of recurring diarrhea caused by toxin produced by Clostridium difficile. A preparation of Lactobacillus brevis has been found to be effective in the treatment of recurrent headache. Lactobacilli have also been successfully used as adjuvants in the treatment of fungal and protozoal vaginitis and in the treatment of non-specific bacterial vaginitis. The nutritional and therapeutic benefits of lactobacilli are summarized in Figure 1.

Studies on rats have shown improved growth rate and increased feed efficiency when the rats were fed with yogurt containing lactobacilli. Improved feed efficiency in rabbits fed diets supplemented with L. sporogenes has been reported. Although several lactobacilli require B - vitamins for growth, some of these organisms are capable of synthesizing B-vitamins. The levels of some of the B-vitamins in yogurt have been controled. Similarly, bioavailability of copper, iron, calcium, zinc, manganese and phosphorus was increased in yogurt fed rats.

Background information

Lactic acid bacteria have the property of producing lactic acid from sugars by a process called fermentation. The genera Bacillus, Leuconostoc, Pediococcus and Streptococcus are important members of this group. The taxonomy of lactic acid bacteria has been based on the gram reaction and the production of lactic acid from various fermentable carbohydrates.

Lactobacilli are gram positive and vary in morphology from long, slender rods to short coccobacilli, which frequently form chains. Their metabolism is fermentative; some species are aerotolerant and may utilize oxygen through the enzyme flavoprotein oxidase, while others are strictly anaerobic. While spore bearing Bacillus coagulans are facultative anaerobes, the rest are strictly anaerobic. The growth is optimum at pH 5.5-5.8 and the organisms have complex nutritional requirements for amino acids, peptides, nucleotide bases, vitamins, minerals, fatty acids and carbohydrates.

Proteolysis : Proteins are broken down into easily assimilable components.
Lipolysis: Complex fat is broken down into easily assimilable components.
Lactose metabolism: Lactic acid bacteria have the enzymes b- galactosidase, glycolases and lactic dehydrogenase (LDH) which produce lactic acid from lactose.
Production of bacteriocins: Bacteriocins are proteins or protein complexes with bactericidal activities directed against species which are closely related to the producer bacterium. The inhibitory activity of L. sporogenes and lactobacilli towards putrefactive organisms is thought to be partially due to the production of bacteriocins.
Production of other antagonistic substances: Lactic acid bacteria also inhibit the growth of harmful putrefactive microorganisms through other metabolic products such as hydrogen peroxide, carbon dioxide and diacetyl.
Synthesis of B- vitamins: Friend et al. reported that the B-vitamin content of fermented milk products was a function of species as well as the strain of lactic acid bacteria used in their manufacture. Similarly, vitamins are synthesized by the lactic cultures in the gut microflora, in symbiosis with other flora.

Benefits of Bacillus coagulans as a probiotic

Clinical studies have revealed that L. sporogenes can be successfully implanted in the intestine. As explained in an earlier section, L. sporogenes satisfies the essential requirements of an efficient probiotic. Preparations of L. sporogenes in pharmaceutical dosage forms such as tablets, capsules, dried granules or powder have the following characteristics:
Contain a large number of viable lactobacilli that retain viability during preparation in pharmaceutical dosage forms and during storage before consumption. The spores are thermostable as against viable L. acidophilus cells which may not withstand spray drying.
Survive in gastric secretions and bile of the upper digestive tract and reach the intestine safely.
Settle in the digestive tract and produce enough lactic acid and other antagonistic substances to inhibit the growth of pathogenic bacteria.

Being sporulated, they germinate under favorable conditions and produce sufficient viable cells which proliferate and perform vital healthful functions as described earlier. In addition, L. sporogenes spores are semi-resident and are slowly excreted out of the body (7 days after discontinuation of administration)

Toxicological aspects of LactoSpore®

In general, no toxic effects of Lactobacillus administration have been reported, except for metabolic acidosis in cases of ingestion of Lactobacillus preparations with the D (-) optical isomer of lactic acid, especially in association with unbalanced diets. A limit of 200 ml per 10 kg body weight of this isomer per day has therefore been recommended for young children.
No adverse reaction to L. sporogenes has been observed in either clinical or nonclinical studies. L. sporogenes* produces only the L (+) optical isomer of lactic acid.

Recommended dosage

The daily recommended dose is 100 to 200 Million organisms per dose - 3 times daily, in tablets, capsules, chewable tablets, vaginal tablets or ovules, etc...
Figure 4 gives you the recommended dosage in feed and veterinary products.
Sabinsa has studied the heat stability at 90°C and 140°C (stability on viable count of Lactospore with high temperature) and the viable counts remain over 90% even after 150 sec at 90% or 30 sec at 140°C. Virtually 100% of spores are revived, one reason for the choice of Bacillus coagulans (sporogenes), and specific drying method. Spores will not grow during their action, and disappear by natural ways after working, hence the need for regular intake.

Bacillus coagulans or sporogenes: A superior probiotic

L. sporogenes was first isolated and described in 1933 by L.M. Horowitz-Wlassowa and N.W. Nowotelnow and the name was accepted in the fifth edition of " Bergey’s Manual of Determinative Bacteriology". However, it was transferred to Bacillus coagulans in the seventh edition of Bergey’s manual due to simplification in cataloging. However, in honor of the original discoverers, the name Lactobacillus sporogenes is used widely, except for taxonomical purposes. According to the Eighth Edition of Bergey’s Manual of Determinative Bacteriology, "Various spore-bearing rods which produce lactic acid, are facultative or aerobic and catalase positive, have generally and correctly been assigned to the genus Bacillus."

The characteristics of L. sporogenes as cited in Bergey’s Manual (Seventh Edition) and other sources are: "Gram - positive spore-forming rods 0.9 by 3.0 to 5.0 micron size, aerobic to microaerophilic, producing L(+)-(dextrorotatory) lactic acid homofermentatively." Since L. sporogenes exhibits characteristics typical of both genera Lactobacillus and Bacillus, its taxonomic position between the families Lactobacillaceae and Bacillaceae has often been discussed. This, along with the fact that there is no universally accepted official classification leaves room for controversy in the nomenclature.

Clinical Studies

Gastro-intestinal and associated effects

It is evident that the administration of L. sporogenes markedly improved the general clinical condition of the subjects and provided relief from intestinal disorders and allergic skin conditions. Allergic skin conditions can be related to an imbalance of intestinal flora in the subject. This condition was therefore corrected by L. sporogenes therapy in these trials (from clinical reports by Pediatric Clinic of Shinko Hospital, Medical Clinic of Kugason Hospital, Clinic of Kanto Teishin Hospital, Medical Clinic of Kahoku Hospital, Pediatric Clinic of Ebara Hospital).
Acute and chronic intestinal catarrh (38 subjects): Recovery from diarrhea to regular normal stools; general symptoms including anorexia improved
Diarrhea (15 subjects): Recovery from diarrhea to regular, normal stools from third to fourth day
Constipation (10 subjects): Recovery to normal stools and disappearance of abdominal distention
Abnormal intestinal fermentation (9 subjects): Vomiting and nausea disappeared; appetite improved; stools became normal and regular; diarrhea and stomach ache cured
Dyspepsia infantum (26 subjects): general conditions and nature of stools improved. Frequency of stools decreased to half or less than that before medication.
Allergic skin diseases (5 subjects): Obvious eruptions of strophulus and eczema decreased from the third day (topical therapy employed concomitant
Miscellaneous symptoms (10 subjects): Response seen in anorexia of nervous type and malnutrition in infants
Studies with SPORLACO: A total of 60 cases of neonatal diarrhea with watery stool frequency greater than 6 were examined for efficacy of SPORLAC treatment. Based on the suggested dosage level of SPORLAC at 5 million spores per kilogram body weight, each neonate was given a spore level of about 15 million spores per day. Some of the subjects had associated symptoms in addition to diarrhea.

Hypocholesterolemic effects

Short term hypolipedemic effects of oral L. sporogenes* therapy (360 million spores per day in tablet form) were studied in 17 patients10 (15 men and 2 women in the 32-61 year age group) with type II hyperlipidemia in an open label fixed dose trial. Total serum cholesterol, LDL-cholesterol and total cholesterol to HDL-cholesterol and LDL-cholesterol to HDL-cholesterol ratios (p < 0.001) was reduced significantly over a period of three months. HDL-cholesterol was marginally increased (43.6±7 mg/dl vs 46.8± 8.9 mg/dl, p < 0.05). there was however no change in serum triglyceride levels. The results are shown in Figure 2.

Non-specific vaginitis

Non-specific vaginitis is caused by a variety of pathogens including staphylococci, streptococci, pneumococci and E. coli. It may also be induced by a variety of causes including chemicals, drugs, surgical procedures, trauma and foreign bodies. L. sporogenes administration to increase the vaginal acidity by the action of the lactic acid (produced by Lactobacillus) on glycogen in the vaginal epithelial tissues was adopted in a clinical trial on 44 patients (figure 3). In comparison with a clinical trial using M.T.P. vaginal pessaries containing broxyquinoline and brobenzoxeldine where only 26.67% of cases studied were cured. It can be seen that L. sporogenes therapy is the better alternative in the treatment of non-specific vaginitis. L. sporogenes therapy provided complete relief to 91% of the patients and partial relief to the remaining 9%.

Aphthous stomatitis and glossitis

Sharma et al noted that Sporalco therapy is one of the best available methods to treat recurrent oral ulcerations. At the dosage level of two tablets thrice daily for five days, (corresponding to 120 million spores of L. sporogenes per day), aphthous stomatitis was cured in two to three days.

Veterinary probiotic

The effects of L. sporogenes on the growth performance and changes in microbial flora of the feces and intestinal contents of broiler chicks were investigated. It was found that body weight gain of chicks fed L. sporogenes at the level of 0.04% was significantly higher than that of the control. Feed efficiency was remarkably improved by the addition of L. sporogenes at the level of 0.04% and Zn-bacitracin at the 0.05% level. The L. sporogenes fed group showed better feed efficiency. Intestinal pH was reduced and fecal ammonia concentrations were slightly reduced. In feces, L. sporogenes and lactobacilli counts were increased and staphylococci and coliforms reduced by the addition of L. sporogene (figure 4).

Properties of the spores:

The spores of L. sporogenes are resistant to heat and other adverse environmental conditions, surviving even under a temperature of 100° C for twenty minutes in phosphate buffer at pH 7. The spores germinate in malt broth even in the presence of dilute hydrochloric acid (at pH 4.6 to 5.6), caustic soda solution (pH 7.6-9.6), saline solution (5%, 10%, 20% concentration), a 2.5% solution of boric acid as well as distilled water. The spores are two to eight times more resistant to antibiotics than the vegetative cells.


Gontran Gaillot